Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 1, 2006, Pages 254-259

  Li, Xia ^a   Need, Anne B ^a   Baez, Melvyn ^a   Witkin, Jeffrey M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; ANTIDEPRESSANT AGENT; IMIPRAMINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STABILITY; FORCED SWIMMING TEST; IMMOBILIZATION; KNOCKOUT MOUSE; MALE; MONOAMINERGIC SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; WILD TYPE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; IMIPRAMINE; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PYRIDINES; RECEPTORS, METABOTROPIC GLUTAMATE; SWIMMING; THIAZOLES;

EID: 33748999574     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.103143     Document Type: Article

References (37)

1. Alt A, Nisenbaum ES, Bleakman D, and Witkin JM (2006) A role for AMPA receptors in mood disorders. Biochem Pharmacol 71:1273-1288.
2. 3H]3-methoxy-5- (pyridin-2-ylethynyl) pyridine). Eur J Pharmacol 473:35-40.
3. Belozertseva IV, Kos T, Popik P, Danysz W, and Bespalov AY (2006) Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol, in press.
4. Brodkin J, Bradbury M, Busse C, Warren N, Bristow LJ, and Varney MA (2002) Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur J Neurosci 16:2241-2244.
5. Brody SA, Conquet F, and Geyer MA (2004a) Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology (Berl) 172:187-195.
6. Brody SA, Dulawa SC, Conquet F, and Geyer MA (2004b) Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 9:35-41.
7. Busse CS, Brodkin J, Tattersall D, Anderson JJ, Warren N, Tehrani L, Bristow LJ, Varney MA, and Cosford ND (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29:1971-1979.
8. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M, Orzi F, and Conquet F (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 4:873-874.
9. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
10. Cosford ND, Roppe J, Tehrani L, Schweiger EJ, Seiders TJ, Chaudary A, Rao S, and Varney MA (2003) 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46:204-206.
11. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, et al. (1999) 2-Methyl-6-(phenylethynyl) pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-1503.
12. Heidbreder CA, Bianchi M, Lacroix LP, Faedo S, Perdona E, Remelli R, Cavanni P, and Crespi F (2003) Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo. Synapse 50:269-276.
13. Jia Z, Lu Y, Henderson J, Taverna F, Romano C, Abramow-Newerly W, Wojtowicz JM, and Roder J (1998) Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn Mem 5:331-343.
14. Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristow LJ, and Conn PJ (2003) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306:116-123.
15. Klodzinska A, Tatarczynska E, Chojnacka-Wojcik E, Nowak G, Cosford ND, and Pilc A (2004) Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 47:342-350 [published erratum seems in Neuropharmacology (2004) 47:1115].
16. Kugaya A and Sanacora G (2005) Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 10:808-819.
17. Li X, Witkin JM, Need AB, and Skolnick P (2003) Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell Mol Neurobiol 23:419-430.
18. Mathiesen JM, Svendsen N, Brauner-Osborne H, Thomsen C, and Ramirez MT (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138:1026-1030.
19. Page ME, Szeliga P, Gasparini F, and Cryan JF (2005) Blockade of the mGlu5 receptor decreases basal and stress-induced cortical norepinephrine in rodents. Psychopharmacology (Berl) 179:240-246.
20. Palucha A, Branski P, Szewczyk B, Wieronska JM, Klak K, and Pilc A (2005) Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 81:901-906.
21. Palucha A, Branski P, Tokarski K, Bijak M, and Pilc A (1997) Influence of imipramine treatment on the group I of metabotropic glutamate receptors in CA1 region of hippocampus. Pol J Pharmacol 49:495-497.
22. Paul IA and Skolnick P (2003) Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 1003:250-272.
23. Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wislowska A, Plaznik A, Bespalov AY, and Danysz W (2005) Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 514:25-34.
24. Pilc A, Branski P, Palucha A, Tokarski K, and Bijak M (1998) Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA1 region. Eur J Pharmacol 349:83-87.
25. Pilc A, Klodzinska A, Branski P, Nowak G, Palucha A, Szewczyk B, Tatarczynska E, Chojnacka-Wojcik E, and Wieronska JM (2002) Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 43:181-187.
26. Pilc A and Legutko B (1995) Antidepressant treatment influences cyclic AMP accumulation induced by excitatory amino acids in rat brain. Pol J Pharmacol 47:359-361.
27. Porsolt RD, Bertin A, and Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336.
28. Roppe JR, Wang B, Huang D, Tehrani L, Kamenecka T, Schweiger EJ, Anderson JJ, Brodkin J, Jiang X, Cramer M, et al. (2004) 5-[(2-Methyl-1,3-thiazol-4-yl) ethynyl]-2,3′-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity. Bioorg Med Chem Lett 14:3993-3996.
29. Schoepp DD and Conn PJ (1993) Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 14:13-20.
30. Skolnick P, Legutko B, Li X, and Bymaster FP (2001) Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res 43:411-423.
31. Smialowska M, Szewczyk B, Branski P, Wieronska JM, Palucha A, Bajkowska M, and Pilc A (2002) Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus Neuropharmacology 42:1016-1023.
32. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, and Schreiber R (2003) Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257-277.
33. Spooren W and Gasparini F (2004) mGlu5 receptor antagonists: a novel class of anxiolytics? Drug News Perspect 17:251-257.
34. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, and Schoepp DD (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4:131-144.
35. Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, Hodgson RA, Lu SX, Nicolussi E, Pond AJ, et al. (2005) The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl) 179:207-217.
36. Wieronska JM, Branski P, Szewczyk B, Palucha A, Papp M, Gruca P, Moryl E, and Pilc A (2001) Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression. Pol J Pharmacol 53:659-662.
37. Wieronska JM, Szewczyk B, Branski P, Palucha A, and Pilc A (2002) Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 23:213-216.